Adicet Bio Highlights 2026 Milestones and Pipeline Progress

January 7, 2026 — Leads & Copy —

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company, has provided corporate updates and highlighted upcoming milestones for 2026, focusing on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.

Chen Schor, President and Chief Executive Officer of Adicet Bio, stated that enrollment in the prula-cel Phase 1 program in autoimmune diseases has more than doubled since October, with over 20 patients as of December 31, 2025. The company has reached regulatory alignment with the FDA for outpatient dosing of SLE and LN patients receiving prula-cel and is advancing its Phase 1 study in treatment-refractory RA, comparing prula-cel following cyclophosphamide alone versus cyclophosphamide/fludarabine conditioning.

Adicet Bio is also advancing its pipeline, including ADI-212, a next-generation, gene-edited and armored solid tumor candidate, which is advancing towards a regulatory filing in the first half of 2026. Recent achievements position the company as it prepares for a pivotal study and continues to advance its pipeline.

The prula-cel Phase 1 program is enrolling patients across seven different autoimmune diseases: LN, SLE, systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS), AAV, and treatment-refractory RA. The FDA has granted Fast Track Designation to prula-cel for the potential treatment of relapsed/refractory class III or class IV LN, refractory SLE with extrarenal involvement, and SSc.

In November 2025, the company reached alignment with the FDA to allow LN and SLE patients to be dosed with prula-cel in the outpatient setting in ongoing and future clinical trials.

In October 2025, Adicet announced the dosing of the first treatment-refractory RA patient in a Phase 1 study, evaluating two conditioning regimens: cyclophosphamide alone and cyclophosphamide with fludarabine. The primary objectives of the study are to evaluate the safety and tolerability of prula-cel. Secondary objectives include measuring cellular kinetics, pharmacodynamics, and disease activity scores.

Also in October 2025, the company reported positive preliminary safety and efficacy data from the Phase 1 clinical trial of prula-cel in patients with LN and SLE, highlighting rapid and sustained reductions in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) score and Physician’s Global Assessment (PGA), improved renal function, and a favorable safety and tolerability profile as of the August 31, 2025, data cut-off date.

Adicet is continuing preclinical development of ADI-212, engineered to express a novel CAR binder, integrate membrane-tethered IL-12 armoring, and utilize CRISPR/Cas9 mediated disruption of subunit 12 of the mediator complex (MED12) to enhance potency in solid tumors and deliver multiple anti-tumor mechanisms of action within the tumor microenvironment. In October 2025, preclinical data from ADI-212 were presented at the 32nd Annual Prostate Cancer Foundation Scientific Retreat.

Adicet successfully raised approximately $74.8 million in net proceeds through an underwritten registered direct offering of equity securities in October 2025, extending its cash runway into the second half of 2027.

Strategic priorities and anticipated key milestones for 2026 include presenting new and updated clinical data from the Phase 1 study evaluating prula-cel throughout 2026, sharing a clinical update in LN, SLE, and SSc in the first half of 2026, and sharing another clinical update from the study in the second half of 2026.

Adicet plans to request a meeting with the FDA in the second quarter of 2026 to inform potential pivotal trial design and expects to initiate a pivotal study in LN or LN and SLE patients in the second half of 2026, subject to regulatory clearance. The company is enrolling patients with treatment-refractory RA in its Phase 1 study of prula-cel evaluating the potential to reduce the need for conditioning and expects to provide a clinical update on the Phase 1 RA study in the second half of 2026.

Adicet expects to submit a regulatory filing for ADI-212 for the treatment of mCRPC in the first half of 2026 and expects to initiate clinical startup activities in the second quarter of 2026, subject to regulatory clearance.

Adicet Bio, Inc. is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients.

Contact:

Source: Adicet Bio, Inc.

×

Welcome!

Smallcap Reporter is the source most up-to-date real-time, direct-from-source News Tips and Story Leads.

By Subscribing you will receive Daily Smallcap Update each day at 9:30 am ET (Market Open) in your inbox and you can unsubscribe any time.